All Stories

Third Harmonic halves headcount to take urticaria drug into phase 2 despite side effects

Third Harmonic Bio will lay off half of its workforce, the biotech has said as it prepares to take its chronic spontaneous urticaria (CSU) candidate into phase 2.

Feb 11, 2025 - 15:21
 0
Third Harmonic halves headcount to take urticaria drug into phase 2 despite side effects
Third Harmonic Bio will lay off half of its workforce, the biotech has said as it prepares to take its chronic spontaneous urticaria (CSU) candidate into phase 2.
Read More

Tags:

Previous Article

AI-powered sports media company raises $13 million, led by Alexis Ohanian and Gi...

Next Article

UPDATE: Judge temporarily blocks NIH grant changes in 22 states

Related Posts

Encoded lays off 29% of staff to fund Dravet syndrome gene therapy trial

Encoded lays off 29% of staff to fund Dravet syndrome g...

Feb 13, 2025  0

Eli Lilly's next R&D focus: Testing incretin meds in neuro, immunology fields

Eli Lilly's next R&D focus: Testing incretin meds in ne...

Feb 9, 2025  0

Glucotrack’s 3-year diabetes sensor implant clears initial human safety trial

Glucotrack’s 3-year diabetes sensor implant clears init...

Feb 9, 2025  0